• Diagnosed with obstructive hypertrophic cardiomyopathy (HCM) consistent with current American College of Cardiology Foundation/American Heart Association and European Society of Cardiology guidelines.

• Has unexplained LV hypertrophy with nondilated ventricular chambers in the absence of other cardiac (ie, hypertension, aortic stenosis) or systemic disease and with maximal LV wall thickness ≥ 15 mm (or ≥ 13 mm with positive family history of hypertrophic cardiomyopathy).

• Has LVOT (Valsalva left ventricular outflow tract) peak gradient ≥ 50 mmHg during screening as assessed by TTE at rest, Valsalva maneuver, or post exercise LVOT peak gradient.

• Has LVOT peak gradient with Valsalva at screening TTE of ≥ 30 mmHg.

• Has adequate acoustic windows to enable accurate TTEs.

• Has New York Heart Association (NYHA) Class II or III symptoms at screening.

• Body weight is greater than 45 kg at screening.

• Documentation of LVEF ≥ 55% at rest of screening TTE.